[{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"National Institute for Health Research, UK | Merck Group | Multiple Sclerosis Society of Great Britain & Northern Ireland | National Multiple Sclerosis Society | Barts & The London NHS Trust","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen Mary University of London \/ National Institute for Health Research, UK | Merck Group | Multiple Sclerosis Society of Great Britain & Northern Ireland | National Multiple Sclerosis Society | Barts & The London NHS Trust","highestDevelopmentStatusID":"9","companyTruncated":"Queen Mary University of London \/ National Institute for Health Research, UK | Merck Group | Multiple Sclerosis Society of Great Britain & Northern Ireland | National Multiple Sclerosis Society | Barts & The London NHS Trust"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen Mary University of London \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Queen Mary University of London \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Hematologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Maryland, Baltimore \/ Hematologics","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Hematologics"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Cancer Institute | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Cancer Institute | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ National Cancer Institute | Bayer AG"},{"orgOrder":0,"company":"University of Washington","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ AbbVie Inc"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ EMD Serono","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ EMD Serono"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UT Southwestern Medical Center \/ EMD Serono","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ EMD Serono"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Prime Therapeutics \/ EMD Serono"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ AbbVie Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul \/ Merck Group","highestDevelopmentStatusID":"11","companyTruncated":"Pontificia Universidade Cat\u00f3lica do Rio Grande do Sul \/ Merck Group"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Disintegrating","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"dr hab. n. med. Agnieszka Wierzbowska","sponsor":"Polish Adult Leukemia Group | Copernicus Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"dr hab. n. med. Agnieszka Wierzbowska","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"dr hab. n. med. Agnieszka Wierzbowska \/ Polish Adult Leukemia Group | Copernicus Memorial Hospital","highestDevelopmentStatusID":"10","companyTruncated":"dr hab. n. med. Agnieszka Wierzbowska \/ Polish Adult Leukemia Group | Copernicus Memorial Hospital"},{"orgOrder":0,"company":"Keith Edwards","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Keith Edwards","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keith Edwards \/ EMD Serono","highestDevelopmentStatusID":"11","companyTruncated":"Keith Edwards \/ EMD Serono"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ The University of Texas MD Anderson Cancer Center"}]
Find Clinical Drug Pipeline Developments & Deals for Cladribine
Details :
Company intends to use the net proceeds from the Offering for developing BNT23001 (cladribine), a sublingual thin-film, works as a DNA synthesis inhibitor, for the treatment of Multiple Sclerosis.
Details :
The proceeds from the financing will be used to fund the clinical development of company's lead product Cladribine-Generic (cladribine). It is being evaluated for the treatment of Multiple Sclerosis.
Details :
BNT23001 (cladribine) is a sublingual thin-film formulation, works as a DNA synthesis inhibitor. It is being evaluated in for the treatment of Multiple Sclerosis.
Details :
Cladribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Details :
Mavenclad (Cladribine) is a orally administered DNA synthesis inhibitor. It is being evaluated in for the treatment of Generalized Myasthenia Gravis.
Details :
The agreement will serve as the foundation for BioNxt's future product development, particularly its pipeline, which includes Cladribine-Generic (cladribine) oral dissolvable drug formulations.
Details :
The net proceeds will be used for the development and commercialization of cladribine. It involves targeting the cells of the adaptive immune system on treating multiple sclerosis.
Details :
Cladribine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Details :
The Company intends to use the net proceeds research, development, and commercialization programs, including its proprietary ODF Cladribine dosage form, directed at the multiple sclerosis.
Details :
Cladribine, an oral dissolvable film product, is incorporated into DNA strands where it inhibits DNA synthesis and repair, it is being developed for the treatment of Multiple Sclerosis.
Reset All
